Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of health-care revenue-cycle-management specialist Accretive Health
So what: Accretive's headline non-GAAP earnings per share came in at $0.06 per share, right in line with Wall Street's expectations. Though the positive profit reversed a loss from last year, the prior loss owed to preferred share dividends. Year over year, the company's operating profit fell 36%, partly because of softer-than-expected revenue -- which management chalked up to timing of signing contracts -- and higher costs associated with its Quality and Total Cost of Care program.
Now what: Management's outlook likely had a lot to do with the stock's sell-off today. Revenue in the upcoming quarter could fall short of the bar that analysts had set. In addition, investors may be a bit skittish because Accretive just hit the public markets earlier this year. And I tend to be a bit skeptical of companies that focus on adjusted non-GAAP numbers, particularly when -- as with Accretive -- the adjustments primarily focus on ignoring the cost of share-based compensation. Accretive has an interesting business, but investors will want to keep this stock on a short leash -- if they keep it at all.
Want to keep up to date on Accretive Health? Add it to your watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer does not own shares of any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy assures you no Wookiees were harmed in the making of this article.